8T8.F TRANSMEDICS GROUP
- Market cap
- EUR 2.43B
- P/E
- 22.1x
- P/B
- 4.95x
- ROE
- 9.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 8T8.F undervalued?
Graham number8T8.F trades 120.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
TRANSMEDICS GROUP fundamental analysis
No fundamental analysis for TRANSMEDICS GROUP yet.
TRANSMEDICS GROUP stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About TRANSMEDICS GROUP
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG fo…
Full company profileTRANSMEDICS GROUP financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
TRANSMEDICS GROUP annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 30.3M | 93.5M | 242M | 442M | 605M | 756M |
| Gross Profit | 21.2M | 65.3M | 154M | 262M | 363M | 444M |
| Operating Income | -39.4M | -31.4M | -28.7M | 37.5M | 109M | 86.9M |
| EBITDA | - | -29.0M | -7.70M | 69.9M | 148M | 142M |
| Net Income | -44.2M | -36.2M | -25.0M | 35.5M | 190M | 52.1M |
| EPS | -1.59 | -1.13 | -0.77 | 1.05 | 5.55 | 1.50 |
| Balance Sheet | ||||||
| Total Assets | 135M | 277M | 706M | 804M | 1.07B | 1.52B |
| Total Liabilities | 67.0M | 89.8M | 569M | 575M | 595M | 967M |
| Shareholders' Equity | 67.9M | 187M | 137M | 229M | 473M | 551M |
| Cash & Short-term Investments | 25.6M | 201M | 395M | 337M | 488M | 493M |
| Cash Flow | ||||||
| Operating Cash Flow | -28.9M | -45.8M | -13.0M | 48.8M | 193M | 104M |
| Capital Expenditure | 3.52M | 11.9M | 179M | 130M | 59.3M | 69.5M |
| Free Cash Flow | -32.4M | -57.7M | -192M | -80.9M | 134M | 34.3M |
| Ratios | ||||||
| ROE | -65.2% | -19.3% | -18.2% | 15.5% | 40.2% | 9.5% |
| ROA | -32.8% | -13.1% | -3.5% | 4.4% | 17.8% | 3.4% |
| Net Profit Margin | -146.1% | -38.8% | -10.4% | 8.0% | 31.4% | 6.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
TRANSMEDICS GROUP dividends
TRANSMEDICS GROUP has not paid dividends in the last 5 fiscal years.
Who owns TRANSMEDICS GROUP
- Insiders 3.71%
- Institutions 96.29%
- Public & others 0.00%
- Shares outstanding 34.7M
- Free float 33.6M
TRANSMEDICS GROUP company profile
- Company name
- TRANSMEDICS GROUP
- Ticker
- 8T8.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 898
- Fiscal year end
- December
- Address
- 200 Minuteman Road, Andover, MA, United States, 01810
- Phone
- 978 552 0900
- Website
- transmedics.com
About TRANSMEDICS GROUP
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
TRANSMEDICS GROUP management
6- Dr. Waleed H. Hassanein M.D.Founder, President, CEO & Director · born 1968
- Mr. Nicholas CorcoranSenior Vice President of Supply Chain & Operations · born 1982
- Dr. Tamer I. Khayal M.D.Senior Vice President of International · born 1969
- Mr. Fernando AraujoChief Financial Officer & Treasurer · born 1980
- Mr. Matthew ForsythSenior VP, General Counsel & Corporate Secretary
- Ms. Miriam C. Provost Ph.D.Vice President of Global Regulatory Affairs · born 1961